A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

Condition:   Malignant Melanoma Interventions:   Drug: Tilsotolimod;   Drug: Saline (0.9% sodium chloride) Sponsors:   A.J.M. van den Eertwegh;   Idera Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials